{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'For CMI the analysis will be performed on all the samples available (TVC) due to low', 'number of samples.', 'Compared to the criteria applicable for the ATP cohort for analysis of safety, additional', 'criteria for the ATP cohort for immunogenicity were the following:', 'Administration of any medication forbidden by the protocol', 'Underlying medical condition forbidden by the protocol', 'Concomitant infection related to the disease under study (VZV) which might have', 'influenced immune response', 'Concomitant infection not related to the disease under study (VZV) which might', 'have influenced immune response', 'Vaccination done but not compliant with Dose 1- - Dose 2 vaccination schedules', '(dates of vaccination not corresponding to protocol intervals or unknown vaccination', 'dates)', 'Blood sample taken but not compliant with blood sampling schedules (dates of BS', 'not corresponding to adapted protocol intervals or unknown BS/vaccination dates)', 'Serological results not available for antigens POST vaccination (including lost', 'samples, not done, unable to test, absence of parallelism)', 'Subject did not belong to the specified Immunogenicity subset', 'The subject did not receive two doses', '10.6.', 'Derived and transformed data', '10.6.1.', 'Handling of missing data', 'For a given subject and a given measurement, missing or non-evaluable measurements', 'will not be imputed for the analysis. The missing endpoint and censoring are supposed to', 'occur independently, and the pattern of the missingness being either Completely At', 'Random (MCAR) or Missing At Random (MAR) only.', 'For the analysis of solicited symptoms, missing or non-evaluable measurements will not', 'be replaced. Therefore, the analysis of the solicited symptoms based on the TVC will', 'include only subjects/doses with documented safety data (i.e., symptom screen/sheet', 'completed).', 'For the analysis of unsolicited AEs/SAEs/concomitant medication, all vaccinated subjects', 'will be considered and subjects who did not report an event will be considered as subjects', 'without an event.', 'For a given subject and a given immunogenicity measurement, missing or non-evaluable', 'measurements will not be replaced. Therefore, an analysis will exclude subjects with', 'missing or non-evaluable measurements.', '11-FEB-2019', '33', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', '10.6.2.', 'Humoral and CMI immune response', 'The derivation of data transformed variables for humoral immunogenicity and CMI will', 'be consistent with the derivation provided in the Zoster-006 and Zoster-022 protocols,', 'and the details will be included in the statistical analysis plan.', '10.7.', 'Statistical methods', 'Age in years will be computed as the difference between the date of completion of the', 'QoL questionnaire collected at Month 0 and the date of birth.', 'As this is an exploratory analysis, no adjustment will be done for multiple comparisons', '(i.e. a 2-sided significance level of 0.05 will be used).', 'Spearman correlations coefficients will be presented to display the relationships between', 'pairs of variables. In addition, particularly for the QoL variables, the variance inflation', 'factor and the condition indices for testing multicollinearity will be estimated.', 'A bootstrap analysis will be carried out to evaluate the robustness of the results with', 'respect to the selection of variables in the final multivariate model.', 'All analyses will be carried out using SAS Version 9.1.3 or later.', 'GSK vaccines will be responsible for performing the statistical analysis.', '10.7.1.', 'Quality of Life Questionnaires', 'The EQ-5D and SF-36 QoL questionnaires have been completed by subjects enrolled in', 'ZOSTER-006 and ZOSTER-022. Questionnaires were completed by all subjects to assess', 'the frailty of subjects enrolled in ZOSTER-006 and ZOSTER-022 and also the existence', 'of predictive factors for the development of HZ. Both the EQ-5D and SF-36', 'questionnaires are international standards and have been appropriately validated.', '10.7.2.', 'SF-36 questionnaire', 'The SF-36 is a multi-purpose health survey with 36 questions underlying the construction', 'of 8 scales [Ware, 2001]. All but one of the 36 items (self-reported health transition) are', 'used to score the eight SF-36 scales (see Table 2). Each item is used in scoring only one', 'scale. Scale scores are to be constructed following the summated ratings and standardized', 'SF-36 scoring algorithms. See APPENDIX A for a sample of SF-36 questionnaire.', '11-FEB-2019', '34', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}